These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 17803331)

  • 21. Valuing health across the lifespan: health state preferences for seasonal influenza illnesses in patients of different ages.
    Prosser LA; Payne K; Rusinak D; Shi P; Uyeki T; Messonnier M
    Value Health; 2011 Jan; 14(1):135-43. PubMed ID: 21211495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring Health Utilities in Children and Adolescents: A Systematic Review of the Literature.
    Thorrington D; Eames K
    PLoS One; 2015; 10(8):e0135672. PubMed ID: 26275302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications.
    De Civita M; Regier D; Alamgir AH; Anis AH; Fitzgerald MJ; Marra CA
    Pharmacoeconomics; 2005; 23(7):659-85. PubMed ID: 15987225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Review of the Development and Application of Generic Multi-Attribute Utility Instruments for Paediatric Populations.
    Chen G; Ratcliffe J
    Pharmacoeconomics; 2015 Oct; 33(10):1013-28. PubMed ID: 25985933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economic value of life: linking theory to practice.
    Landefeld JS; Seskin EP
    Am J Public Health; 1982 Jun; 72(6):555-66. PubMed ID: 6803602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
    Hawton A; Shearer J; Goodwin E; Green C
    Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
    van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
    Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years.
    Franic DM; Bothe AK; Bramlett RE
    J Fluency Disord; 2012 Dec; 37(4):300-13. PubMed ID: 23218213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the economic foundations of CEA. Ladies and gentlemen, take your positions!
    Brouwer WB; Koopmanschap MA
    J Health Econ; 2000 Jul; 19(4):439-59. PubMed ID: 11010234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valuing reduced antibiotic use for pediatric acute otitis media.
    Meropol SB
    Pediatrics; 2008 Apr; 121(4):669-73. PubMed ID: 18381529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generic health-related quality-of-life assessment in children and adolescents: methodological considerations.
    Ravens-Sieberer U; Erhart M; Wille N; Wetzel R; Nickel J; Bullinger M
    Pharmacoeconomics; 2006; 24(12):1199-220. PubMed ID: 17129075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valuing vaccines using value of statistical life measures.
    Laxminarayan R; Jamison DT; Krupnick AJ; Norheim OF
    Vaccine; 2014 Sep; 32(39):5065-70. PubMed ID: 25045822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Completing costs: patients' time.
    Russell LB
    Med Care; 2009 Jul; 47(7 Suppl 1):S89-93. PubMed ID: 19536025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-benefit analyses in the health-care literature: don't judge a study by its label.
    Zarnke KB; Levine MA; O'Brien BJ
    J Clin Epidemiol; 1997 Jul; 50(7):813-22. PubMed ID: 9253393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response Patterns in Health State Valuation Using Endogenous Attribute Attendance and Latent Class Analysis.
    Hole AR; Norman R; Viney R
    Health Econ; 2016 Feb; 25(2):212-24. PubMed ID: 25521533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On individual preferences and aggregation in economic evaluation in healthcare.
    Liljas B; Lindgren B
    Pharmacoeconomics; 2001; 19(4):323-35. PubMed ID: 11383750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to Measure Costs and Benefits of eHealth Interventions: An Overview of Methods and Frameworks.
    Bergmo TS
    J Med Internet Res; 2015 Nov; 17(11):e254. PubMed ID: 26552360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodological and applied concerns surrounding age-related weighting within health economic evaluation.
    Petrou S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):729-40. PubMed ID: 25040009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valuing SF-6D Health States Using a Discrete Choice Experiment.
    Norman R; Viney R; Brazier J; Burgess L; Cronin P; King M; Ratcliffe J; Street D
    Med Decis Making; 2014 Aug; 34(6):773-86. PubMed ID: 24025661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.